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1 ABSTRACT
The matrix of blood is a liquid plasma that transports molecules and blood
cells within vessels lined by endothelial cells. High-mobility group B1 (HMGB1) is a
protein expressed in blood cells. Under normal circumstances, HMGB1 is virtually
absent from plasma, but during inflammation or trauma its level in plasma is
increased. In resting and quiescent cells, HMGB1 is usually localized in the
intracellular compartment, with the exception of motile cells that express HMGB1 on
their outer surface to mediate cell migration. During cell transformation or immune
cell activation HMGB1 can be actively secreted outside of the cell. Further, when a
cell is damaged, HMGB1 can passively leak into extracellular environment.
Extracellular HMGB1 can then participate in regulation of the immune response and
under some conditions it can mediate lethality in systemic inflammatory response.
The aim of this study was to evaluate the expression and functions of HMGB1
in  cells  of  the  vascular  system and  to  investigate  the  prognostic  value  of  circulating
HMGB1 in severe sepsis and septic shock. HMGB1 was detected in platelets,
leukocytes, and endothelial cells. HMGB1 was released from platelets and leukocytes,
and it was found to mediate their adhesive and migratory functions. During severe
infections the plasma levels of HMGB1 were elevated; however, no direct correlation
with lethality was found. Further, the analysis of proinflammatory mechanisms
suggested that HMGB1 forms complexes with other molecules to activate the immune
system.
In conclusion, HMGB1 is expressed in the cells of the vascular system, and it
participates in inflammatory mechanisms by activating platelets and leukocytes and
by mediating monocyte migration.
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2 REVIEW OF THE LITERATURE
2.1 HIGH-MOBILITY GROUP PROTEINS
2.1.1 High-mobility group protein family
 The term “high-mobility group” (HMG) designates a 0.35 M NaCl-
extractable chromatin protein fraction that is soluble in 2% trichloroacetic acid.
Proteins of this fraction have a higher mobility in polyacrylamide gels than
trichloroacetic acid-precipitated proteins, which in turn are called low-mobility group
(LMG) –proteins [1, 2].
HMG proteins consist of three families: HMGA, HMGB, and HMGN.
They all have characteristic sequence motifs; HMGA family members have an ´AT
hook´ motif, HMGB family members an ´HMG box`, and HMGN family members a
´nucleosomal binding domain´ [3].
All HMG proteins have intracellular, mainly nuclear localization. However,
under certain conditions, some HMG proteins may have extranuclear localization [4,
5, 6]. HMG proteins bind to DNA and mediate various biochemical functions, such as
cell cycle regulation and gene expression, through condensing or unfolding of
chromatin [7].
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Figure 1. Schematic picture showing domain organization of HMG-proteins. HMG
domains were analyzed using the ScanProsite program (ExPASy, Swiss Institute of
Bioinformatics, Switzerland). Sequences are shown from amino terminus to the
carboxy terminus. Negatively charged regions are indicated as described by Hock et
al. [8]. Symbols representing specific protein regions are illustrated in the insert.
2.1.1.1 HMGB
Four members of the HMGB family are currently known in mammals:
HMGB1-4 [9]. In addition to mammals, HMGB proteins are widely expressed in
eukaryotic kingdoms [10].
The human HMGB1 gene encodes a protein of 214 amino acids, the HMGB2
gene encodes a protein of 208 amino acids, and the HMGB3 gene encodes a protein
of 199 amino acids. They all have two HMGB boxes (A and B boxes), and an acidic
carboxyl-terminal domain. HMGB4 has two HMGB boxes, but it lacks the acidic tail.
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The HMGB boxes are involved in DNA binding, but the role of the acidic tail remains
incompletely understood. The acidic tail is known to modulate
poly(ADP)ribosylation-regulated nuclear localization of the protein, affect DNA-
binding affinity of A- and B-boxes, and be involved in the pathology of
polyglutamine diseases [11, 12, 13, 14, 15].
In mammals, HMGB1-3 proteins are coded by three intron-containing genes.
HMGB4 is coded by an intronless gene. However, there is an HMGB4 splice variant
that lacks the A box. Multiple HMGB pseudogenes are found in mammalian
genomes, where HMGB3-originated pseudogenes seem to be most prominent [A.
Rouhiainen  and  H.  Rauvala,  unpublished  results].  The  biological  role  of  retroposed
copies of HMGB genes is unknown [16].
2.1.1.1.1 HMGB1 (Amphoterin)
The HMGB1 gene is located in human chromosome 13 [17, 18]. It codes for a
protein of 215 amino acids. HMGB1 is widely expressed in the adult organism, and
during development it is expressed from the zygote stage [19]. HMGB1 is essential
for normal development in mice since the knockout suffers from multiple organ
failure and defects in bone formation, and the animals die soon after birth due to
severe hypoglycemia [20, 21].
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Figure 2. An alignment of mouse HMGB proteins. Sequences were analyzed
using ClustalW in EMBnet (ISREC Bioinformatics Groups, Epalinges, Switzerland).
* = identical amino acids, : = similar amino acids.
There are multiple sizes of HMGB1 transcripts in different species and tissues.
For  example,  rat  HMGB1  gene  is  transcribed  to  at  least  three  different  types  of
mRNA. The variation is most likely due to differences in length of polyadenylation
tails [22]. The conclusion that differences in poly-adenylation cause the changes in
mRNA length and they are not derived from intronless pseudogenes is further
supported by results from studies using chickens. Chickens, lacking HMGB1
pseudogenes have HMGB1 transcripts of multiple sizes, indicating that they are
differently poly-adenylated forms of the HMGB1gene and are not derived from
HMGB1 pseudogenes [23, 24].
Different forms of HMGB1 transcripts are differentially regulated, suggesting
the existence of a regulatory mechanism for HMGB1 at the mRNA level [25].
HMGB1      MGKGDPKKPRGKMSSYAFFVQTCREEHKKKHPDASVNFSEFSKKCSERWKTMSAKEKGKF
HMGB2      MGKGDPNKPRGKMSSYAFFVQTCREEHKKKHPDSSVNFAEFSKKCSERWKTMSAKEKSKF
HMGB3      MAKGDPKKPKGKMSAYAFFVQTCREEHKKKNPEVPVNFAEFSKKCSERWKTMSSKEKSKF
HMGB4      MGEKDQLRPKVNVSSYIHFMLNFRNKFKEQQPNTYLGFKEFSRKCSEKWRSISKHEKAKY
           *.: *  :*: ::*:* .*: . *::.*:::*:  :.* ***:****:*:::* :**.*:
HMGB1      EDMAKADKARYEREMKTYIPPKGETKKKFKDPNAPKRPPSAFFLFCSEYRPKIKGEHPGL
HMGB2      EDLAKSDKARYDREMKNYVPPKGDKKGKKKDPNAPKRPPSAFFLFCSENRPKIKIEHPGL
HMGB3      DEMAKADKVRYDREMKDYGPAKGGKKK--KDPNAPKRPPSGFFLFCSEFRPKIKSTNPGI
HMGB4      EALAELDKARYQQEMMNYIGKR--RKRRKRDPKAPRKPPSSFLLFSRDHYAMLKQENPDW
           : :*: **.**::**  *   :   *   :**:**::***.*:**. :  . :*  :*.
HMGB1      SIGDVAKKLGEMWNNTAADDKQPYEKKAAKLKEKYEKDIAAYRAKGKPDAAKKGVVKAEK
HMGB2      SIGDTAKKLGEMWSEQSAKDKQPYEQKAAKLKEKYEKDIAAYRAKGKSEAGKKGPGRPTG
HMGB3      SIGDVAKKLGEMWNNLSDNEKQPYVTKAAKLKEKYEKDVADYKSKGKFDGAKG----PAK
HMGB4      TVVQVAKAAGKMWSTTDEAEKKPYEQKAALMRAKYFEEQEAYRNQCQ-------------
           :: :.**  *:**.     :*:**  *** :: ** ::   *: : :
HMGB1      SKKKKEEEDDEEDEEDEEEEEEEEDEDEEEDDDDE
HMGB2      SKKKNEPEDEEEEEEEEEEEDDEEEEEDEE-----
HMGB3      VARKKVEEEEEEEEEEEEEEEEEEDE---------
HMGB4      GRKGNFLESAKTSLKQ-------------------
             : :  *. : . ::
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HMGB1 mRNA can be localized to the cell periphery, where it may be translated [26,
27, 28]. However, no differences have been observed in localisation of different poly-
adenylated HMGB1 mRNA forms [28].
Amino acid sequences of HMGB1 proteins are highly conserved between
species; for example, human and rat HMGB1 differ by only two amino acids, which
moreover are replacements of two similar amino acid residues. Although there is no
known amino acid change causing mutations in human HMGB1, single nucleotide
polymorphisms occur [29]. One HMGB1 protein isoform derived from alternatively
spliced messenger has been detected from colon adenocarcinoma cells, suggesting the
existence of HMGB1 polypeptides that vary in amino acid compositions [30].
The structure of HMGB1 has been partially solved. Solution and crystal
structures of the A box show that it forms three  helices that are folded into an L-
shap [31, 32]. The B box forms four  helices in solution that are folded into an L-
shape similar to the A box [33, 34].
In vivo, HMGB1 is often posttranslationally modified, yielding a protein that
has altered affinity for its ligands [35]. An original acid extraction method has been
shown to change in vitro biochemical properties of HMGB1 compared with native
protein; for example, native HMGB1 forms homodimers and oligomers, whereas
acid-extracted HMGB1 does not [36, 37]. In addition, DNA-binding capability and
effects on plasminogen activation of HMGB1 are strongly affected by acid treatment
of the protein [38, 39].
HMGB1 was originally considered a nuclear chromatin component. It binds to
DNA in a sequence-independent manner and interacts with many different nuclear
proteins [10]. However, its exact function in the nucleus remains obscure. Recent
studies with HMGB1-/- cells suggest that HMGB1 is involved in maintenance of
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genome stability, acting as a cofactor of base excision repair and possibly affecting
telomerase functions [10, 40, 41, 42]. Microarray analysis revealed that cells lacking
HMGB1 have altered gene expression of many genes involved in intracellular
signaling, apoptosis, and cell cycle pathways. Further, knockout studies suggested that
different cell types utilize nuclear HMGB1 in different ways [43].
In addition to the original finding that HMGB1 is a nuclear protein, it was
later found also to be both a cytoplasmic [44] and extracellular protein [36, 45].
HMGB1 can be localized to the cell periphery and is actively secreted from some
cells, although it lacks a classical signal sequence for the endoplasmic reticulum and
Golgi-mediated secretion route [39, 46]. Thus, its secretion mechanism is unknown.
The chemical structure of extracellularly secreted HMGB1 has not been fully
determined, although a protein form methylated and/or acetylated in lysine appears to
be secreted from lymphocytes and monocytes, respectively [47, 48, 49]. Further, acid-
treated, secreted extracellular HMGB1 exists as a dimer after acid treatment [50].
In the literature, extracellular HMGB1 is mainly described as an
inflammation-promoting protein [reviewed in 51]. However, there are studies
showing  that  under  certain  circumstances  HMGB1  can  be  an  anti-inflammatory
molecule [52, 53, 54]. Results of these studies indicate that the physiological role of
HMGB1 is incompletely understood and further studies are needed.
Some studies have shown that the genuine HMGB1 polypeptide of eukaryotic
origin is only weakly proinflammatory, whereas the bacterially produced recombinant
protein is highly active. Part of this activity can be mediated by bacterial components
that are carried by HMGB1 [IV, 55, 56, 57, 58, 59]. However, it has been suggested
that eukaryotic HMGB1 released from necrotic cells can induce or enhance
proinflammatory response, although there are controversial results [60, 61, 62]. In
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addition, eukaryotic HMGB1 is able to induce expression of proinflammatory genes
in neutrophils like chemokine ligands and members of interleukin family. These genes
in neutrophils are similarly upregulated by LPS. There are, however, some genes that
are upregulated by HMGB1, but not by LPS, suggesting that HMGB1 itself has some
unique activities on neutrophils [63].
Circulating HMGB1 was originally isolated as a proinflammatory cytokine
that mediates lethality in septic shock [64]. However, the role of circulating HMGB1
is  not  yet  fully  understood,  and  its  role  as  a  proinflammatory  cytokine  has  not  been
clarified in detail [IV, 55]. Nor is the mechanism of HMGB1-mediated lethality fully
explained. For example, high levels of HMGB1 expression in plasma are detected in
liver transplantation patients who survive, suggesting that genuine HMGB1
polypeptide in circulation is not sufficient to mediate lethality, at least not in the short
term  [65]. However, there are animal studies that describe a protective effect of anti-
HMGB1 antibodies against lethality in sepsis, suggesting that HMGB1 mediates
lethality during prolonged complications [64, 66]. Further, anti-HMGB1 antibodies
have a protective effect in other models of inflammatory diseases, e.g. pancreatitis
[67].
In  addition  to  inflammatory  diseases,  HMGB1  is  often  connected  to  cancer,
and its expression is usually increased in transformed tissue and sometimes in blood
plasma [68, reviewed in 69 and 70]. A role in anorexia nervosa is suggested for
HMGB1, and higher plasma HMGB1 levels have been detected during the refeeding
resistance period [71, 72]. HMGB1 levels are often increased in areas of ischemic
insult, and this is thought to mediate ischemia-associated inflammatory response. In
addition, HMGB1 has been suggested to play a role in regeneration of tissue after
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injury. For example, after nerve damage the HMGB1 polypeptide is strongly
upregulated in axons [27].
Nuclear and cytoplasmic HMGB1 have multiple interacting components,
some bind directly to HMGB1 with high affinity, and others compose HMGB1-
binding multicomplexes [7]. The exact effects of these proteins on functions of
HMGB1 are poorly understood.
Extracellular HMGB1 has binding partners both at the cell surface and in the
extracellular matrix. Cell surface binding sites encompass glycoproteins,
proteoglycans, and phospho- and glycolipids. Extracellular matrix HMGB1-binding
site proteins also encompass glycoproteins and proteoglycans (Table 1).
Since the expression of HMGB1 is increased in many diseases and HMGB1
mediates deleterious effects, there is a growing interest in finding small molecule
inhibitors  for  HMGB1.  One  promising  candidate  molecule  that  has  a  well-
documented anti-inflammatory effect and that binds to HMGB1 is glycyrrhizin.
Sakamoto et al. [73] initially showed that glycyrrhizin binds to HMGB1 and affects
DNA-binding properties of HMGB1. Glycyrrhizin has been subsequently shown to
inhibit HMGB1-mediated inflammatory reactions and cell motility [74, 75].
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Table 1. Extracellular binding partners for HMGB1.
Name kd (nM) Role in HMGB1 biology Physiological role
RAGE [76] 10.24±2.84 Colocalizes with HMGB1 in CNS Mediates cell migration
and inflammation
Phosphacan [77] 0.26 Colocalizes with HMGB1 in CNS Coreceptor regulating
cell growth
Neurocan [77] 7.6 - Coreceptor regulating
cell growth
TLR2/4 [78] nd Co-immunoprecipitates with
HMGB1
Mediates inflammation
Glycolipids [79] nd Colocalizes with HMGB1 in CNS Membrane components
Thrombomodulin
[80]
nd Inhibits proinflammatory activity of
HMGB1
Blood coagulation










Heparin [36] nd Blocks HMGB1 interactions with
cells
Blood coagulation
Syndecan-1 [81] nd Colocalize in epithelial cells Regulates cell
migration





Human HMGB2 is coded by a gene located in chromosome 4 [83, 84]. It
codes for a protein of 209 amino acids. HMGB2 is highly expressed during
embryogenesis, and in adults it is mainly expressed in testicles and lymphoid organs
[85]. Mice lacking HMGB2 gene are viable, but knockout males have reduced
fertility. Analysis of the knockout mice revealed that in testis HMGB2 is expressed in
primary spermatocytes and it is involved in germ cell differentiation. Further,
HMGB2 is highly expressed in chondrocytes of the superficial zone in joints, and
knockout mice develop osteoarthritis earlier than wild-type mice [86].
Like HMGB1, HMGB2 is released to extracellular space in various
inflammatory states [87, 88]. HMGB2 binds to fucosylated sugars, including the
Lewis X structure, present in infectious organisms, suggesting a role in immune
defence [89]. Further, binding to RAGE has been suggested for HMGB2 [90]. Thus,
HMGB1 and -2 may compensate for each other. In fact, studies with double
HMGB1/HMGB2 knockouts suggest that these genes have overlapping functions that
may help the single mutant to develop [91].
2.1.1.1.3 HMGB3
HMGB3 (previously known as HMG4 or HMG2b) is coded by a gene in
human chromosome X [92]. Gene codes for protein of 200 amino acids. HMGB3 is
expressed mainly in hematopoietic stem cells. Knockout mice are erythrocytemic
having 10% more red cells than wild-type mice, and enforced HMGB3 expression in
bone marrow inhibits myeloid and B-cell differentiation [93, 94].
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2.1.1.1.4 HMGB4
HMGB4 is a new member of the HMGB-family. It has 186 amino acids, and it
has  both  A  and  B  boxes,  but  it  lacks  the  acidic  carboxyl  terminal  domain.  Human
HMGB4 gene is localized to chromosome 1. HMGB4 is a mammalian-specific gene
probably originating from an intronless HMGB pseudogene. Since birds do not have
HMGB pseudogenes, the occurrence of pseudogene-derived HMGB4 gene in
mammals is consistent with this hypothesis. HMGB4 is much less conserved between
species  than  other  HMGB  genes;  its  carboxyl  terminal  part  in  particular  has  hardly
any conserved amino acids. Currently, little published data on HMGB4 exist.
Affymetrix studies indicate that it is expressed in late and round spermatids [95, 96].
In situ studies reveal its expression in the mouse brain, especially in the hippocampus
and cerebellum internal granule cell layer, and embryonal pancreatic epithelial cells
[97, 98, 99]. Further, partial peptide sequences have been detected in mouse testicles
[100].
2.1.1.2 HMGA
HMGA was previously known as HMGI/Y. According to the new
nomenclature, it is now known as HMGA1 or HMGA2 [3]. These are widely
expressed during development, but are missing in fully differentiated cells [101].
HMGA proteins have AT-hook domains and an acidic carboxyl terminal domain.
The AT-hook domain functions as a DNA-binding region. The acidic carboxyl
terminal domain can mediate protein-protein interactions [101].
The human HMGA1 gene contains eight exons and its mRNA has
alternatively spliced forms that are translated [102]. These transcripts differ in 33
nucleotides coded by exon five, and code for 107 and 96 amino acid proteins in
humans [103]. HMGA1 is also released from cells [104].
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The human HMGA2 gene contains five exons [105]. Similarly to the HMGA1
mRNA, the HMGA2 messenger can be transcribed to alternatively spliced forms
[101]. A full-length human HMGA2 has 109 amino acids [105].
2.1.1.3 HMGN
The HMGN proteins have been previously known as HMG-14 and HMG-17.
Nowadays,  there  are  at  least  three  known  members  of  HMGN  proteins,  HMGN1-3
[106]. They are involved in differentiation and are widely expressed in embryonic
cells, but at lower levels in later developmental stages [101]. HMGN proteins have
three domains: the nuclear localization signal domain, the nucleosome-binding
domain, and the chromatin-unfolding domain [101]. HMGN proteins are associated
with the nucleosome core histones and promote chromatin unfolding and transcription
[107].
Human genes coding for HMGN proteins consist of six exons [108]. They
code for proteins of 77-99 amino acids. As in other HMG families, there are
alternatively spliced mRNAs since at least the HMGN3 transcript can be alternatively
spliced [108].
Evidence indicates that HMGN2 has extracellular functions such as
antimicrobial or tumor metastasis-mediating activities [109, 110, 111]. Thus, all HMG
protein families appear to have members that are released from cells and to possess
extracellular functions.
22
Figure 3. Similarity of predicted domain structures for HMG boxes of mouse HMGB1
and HMGB4. Structures are from amino acid sequences 1-77 (HMGB1 A box), 8-79
(HMGB4 A box), 75-165 (HMGB1 B box), and 67-149 (HMGB4 B box). Pictures
were obtained from MODBASE [112].
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2.2 EXPRESSION OF HMGB1
2.2.1 Expression during development and in adulthood
During development HMGB1 is expressed in many tissues at high levels and
downregulated during differentiation. A good example of this is in the central nervous
system [36]. However, in some cell types, HMGB1 levels remain high in adulthood,
for example in the immune cells of the thymus and in circulating monocytes (II, 113).
The obvious importance of HMGB1 expression during development was
shown in the study of HMGB1-knockout mice. Mice lacking the HMGB1 gene
suffered from multiple organ failure and died soon after birth [20].
Expression of HMGB1 is usually upregulated in inflamed tissue. High
HMGB1 expression is seen in mononuclear phagocytes present in inflamed areas.
Further, cytoplasmic or extracellularly released HMGB1 can be frequently detected.
The origin of extracellularly released HMGB1 can be either the inflamed tissue itself
or infiltrated inflammatory cells [114, 115, 116, 117].
2.2.2 Intracellular expression of HMGB1
HMGB1 was initially described as a nuclear protein [2]. Later, it was found to
be localized both in the nucleus and in the cytoplasm [44].
Nuclear proteins are translated in the cytoplasm, and must be transported to
the nucleus for proper function. The classical nuclear localization signal occurs in
many nuclear proteins and directs them to the nucleus. HMGB1, for instance, has two
nuclear localization signals [49]. However, additional mechanisms for nuclear
targeting of HMGB1 have been suggested. Proteins having an HMGB box can bind to
calmodulin, which mediates their nuclear transport [118].
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Export of HMGB1 from the nucleus to the cytoplasm is mediated by the
chromosome region maintenance 1 protein (CRM1) [119]. Nucleus to cytoplasm
transport is independent of protein synthesis [120]. Further, posttranslational
modifications of HMGB1, including acetylation, serine phosphorylation, methylation,
cysteine reduction/oxidation, and poly(ADP)ribosylation, affect HMGB1 localization
within the cell [49, 120, 121, 122, 123].
HMGB1 moves rapidly within the cell, suggesting that HMGB1 binding to
DNA/chromatin is moderately weak [124]. Photobleaching analyses using enhanced
green fluorescent protein (EGFP) -tagged HMGB1 revealed fast movement within the
nucleus and between the nucleus and the cytoplasm [124]. Although HMGB1 displays
only a weak affinity to DNA/chromatin, this may be functionally sufficient because
the intranuclear concentration is high, in the micromolar range [7].
In  addition,  cytoplasmic  localization  of  HMGB1  can  be  controlled  at  the
transcriptional level. mRNA coding for HMGB1 can be localized to the cell periphery
and translated [26, 28]. This peripheral translation may minimize unnecessary nuclear
transport in situations favoring cytoplasmic or extracellular targeting of HMGB1.
2.2.3 Extracellular expression of HMGB1
Although HMGB1 lacks a signal sequence for secretion, there are several
studies on extracellular HMGB1, a form of HMGB1  first suggested to mediate
neurite outgrowth by Pihlaskari and Rauvala in 1987 [36]. Later, other extracellular
roles for HMGB1 were described, indicating roles as an erythroleukemia
differentiation factor and as a RAGE ligand mediating neurite outgrowth [76, 125].
To date, many research groups have detected extracellular, actively secreted HMGB1
derived from various cell types [126, 127].
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Several studies have examined the nature of extracellular HMGB1. In vivo,
HMGB1 is expressed in extracellular space in humans with infectious and
inflammatory diseases, cancer, and trauma [III, 128]. Extracellular HMGB1 can
activate endothelial cells and mediate leukocyte diapedesis by mechanisms that
involve RAGE   [II, 129, 130]. HMGB1 has been detected in serum, and in cell
culture HMGB1-free serum resulted in reduced myogenic differentiation [I, III, 131].
Some of the extracellular HMGB1 is released during necrosis, and it has been
suggested to mediate inflammatory responses [132, 133]. In addition, apoptotic cells
release HMGB1 [134].
2.2.3.1 Nonclassical secretion
A growing number of secreted proteins lack the amino terminal secretion
signal sequence, but are, nevertheless, actively secreted to the extracellular space like
HMGB1 [reviewed in 135]. Further, identical proteins may have different functions in
different cellular compartments and in different tissues [136]. A great number of
studies show that a single gene product may have alternative localizations and distinct
functions. This suggests that these so-called moonlighting proteins are quite common
in nature [137].
The secreted proteins lacking the secretion signal sequence have some shared
characteristics, although it seems likely that there is no single common mechanism for
nonclassical secretion. Nonclassically secreted proteins are usually small (<45 kDa)
and lack N-glycosylation. Very often only a minor proportion of the intracellular pool
of nonclassically secreted proteins is secreted [138]. Their secretion is unaffected, or
enhanced, by the classical ER-Golgi secretion route inhibitors [139]. Further, protein
synthesis is not required for secretion, at least in the case of HMGB1 and HSP70
[140, 141].
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Some nonclassically secreted proteins share functional similarities with
HMGB1. First, several other HMG proteins are released and possess some
extracellular functions. HMGB2, which is released in vivo to plasma, has very similar
nuclear functions to HMGB1 [3, 87]. HMGA1 has been described as an endothelial
cell-secreted contact activation inhibitor, and HMGN2 as an antibacterial protein
secreted from leukocytes [110, 142]. Second, nuclear proteins other than HMG
proteins are also secreted from cells. DEK is a nuclear protein that serves as an
autoantigen in autoimmune diseases, suggesting exists in the extracellular space.
Further, DEK and another nuclear protein that is secreted from monocytes, the DNA
repair protein Ku, mediate leukocyte migration [143, 144]. Further, histone H3 is a
secreted nuclear protein. Sebocytes, a type of epithelial cells secrete histone H3
packed within microvesicles that are released to the extracellular space [145].
Unacetylated histone H2A in gastric gland cells is secreted and processed to
antimicrobial peptide buforin I by pepsins, in contrast to the acetylated form, which is
localized to the nucleus [146]. Histone H2A.X is another secreted histone type [147].
In addition to full-length histone molecules, a protein coded by alternatively spliced
histone H4 mRNA is secreted [148]. Finally, some nuclear proteins in addition to
HMGB1, e.g. IL-1  and IL-33, have been shown to mediate inflammation [149, 150].
Several mechanisms have been proposed to mediate nonclassical secretion of
proteins. Some involve direct transport through the phospholipid membrane and
others involve packing into and release from intracellular vesicles. A direct transport
mechanism that does not require protein unfolding has been suggested to mediate
FGF-2 export. FGF-2 secretion is dependent on cell surface proteoglycans that may
act as a trap directing FGF-2 molecules to the extracellular space [151, 152, 153].
Vesicular mechanisms are known to mediate nonclassical secretion. One example is
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in Caenorhabditis elegans spermatozoa, which lack components of the classical
secretion route. The Major Sperm Protein is exported through a vesicle budding
mechanism where the protein is packed between the inner and outer membranes of
vesicles [154]. Another well-identified vesicular secretion route is known for IL-1
where secretory lysosomes mediate protein export [155]. A similar secretion route has
suggested for HMGB1 [126]. Some proteins, such as Engrailed homeoprotein and
FGF-9, have an internal signal sequence that directs them to secretion [156, 157].
The role of transporters in nonclassical protein secretion has been widely
studied. One transporter relevant in the case of HMGB1 is ATP binding cassette
transporter 1 [27, 158]. The ATP binding cassette transporters are a family of
transmembrane proteins that have two ATP-binding domains and two transmembrane
domains that both contain six membrane-spanning helices. There are almost 50
known ATP binding cassette transporter genes in the human genome. Inhibitors
against ATP binding cassette transporter 1 inhibit both HMGB1 and IL-1  secretion
from monocytes/macrophages [II, 159]. In addition, ATP binding cassette transporter
1 inhibitors decrease the release of other proteins lacking the secretion signal, annexin
I, macrophage migration inhibitory protein, and Hsp70 [141, 160, 161]. Recently, a
specific ABC transporter, ABCC1 (also called multi-drug resistance protein 1 (MRP-
1)), was suggested to mediate HMGB1 secretion from macrophages [27, 162].
The importance of posttranslational modifications for nonclassical secretion
has been recognized. A very well-known post translational control mechanism occurs
in IL-1 secretion. Both IL-1  and –  are released after proteolysis of the pre-protein
[163]. Extracellular HMGB1 released from neutrophils has a methylated lysine
residue that is not found in HMGB1 released from lymphocytes [47]. Whether this
methylation is required for secretion from neutrophils is not known. Further, HMGB1
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acetylated in lysine has been detected in the extracellular space [47]. S100A12
released from neutrophils has an S-Sulfo-cysteine residue. The S-Sulfo-form of
S100A12 was highly enriched in the extracellular pool, suggesting that S-Sulfo
modification is associated with S100A12 secretion in neutrophils [164]. Finally, the
importance of phosphorylation in the secretion of proteins lacking signal peptide has
been shown. The secreted extracellular forms of annexin I and phosphohexose
isomerase have phosphorylated serine residues [165, 166, 167]. Phosphorylation of
serine residues was suggested to mediate secretion of HMGB1 from macrophages,
and a mutant form linked to GFP protein mimicking serine-phosphorylated HMGB1
was secreted from cells [120].
2.3 HMGB1 RECEPTORS
In the literature, the major cell surface receptor for HMGB1 is the receptor for
advanced glycation end-products (RAGE). However, there is evidence that RAGE is
not the sole receptor for HMGB1 [27, 114, 168]. This is also the case for some other
RAGE ligands, including members of the S100 protein family. Although RAGE
seems to be the major receptor mediating inflammatory effects of S100 proteins,
proteoglycans and ALCAM (CD166) can mediate some effects of the S100 proteins
independently of RAGE [169, 170].
2.3.1 RAGE
RAGE was isolated as an advanced glycation end-product (AGE) binding
protein from the bovine lung [171, 172]. Early studies revealed that RAGE has three
immunoglobulin domains, a single transmembrane domain, and a short cytoplasmic
domain.  RAGE has been subsequently shown to have alternatively spliced forms.
RAGE has a significant role in cell motility; transgenic dominant-negative RAGE or
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RAGE-knockout leukocytes have a reduced ability to migrate to tissues. This leads to
changes in inflammatory responses and regeneration, and during development,
changes in bone morphology [173, 174, 175, 176, 177, 178]. The role of RAGE in
innate immune response, using cecal ligation and a puncture-mediated sepsis model,
was clarified in a recent study [179]. Further, RAGE has roles in adaptive immune
responses [180, 181].
RAGE-HMGB1 interactions in the context of cell migration have been widely
studied. RAGE as an HMGB1 receptor was originally described using protein binding
studies, and in a neurite outgrowth model using primary neurons, RAGE was shown
to mediate HMGB1-dependent neurite outgrowth [76]. Later RAGE-HMGB1
interaction has been described to mediate migration of various cell types, including
smooth muscle cells, cancer cells, and immune cells [182, 183, 184, 185, 186].
However, in some cell types, the role of RAGE as an HMGB1-induced migration-
mediating receptor is not unambiguous. Mesoangioplasts, a type of mesodermal stem
cell that responds to HMGB1, migrate to dystrophic muscle independent of RAGE
expression, and rhabdomyosarcoma cell migration was inversely correlated to RAGE
expression and signaling [50, 114].
The ligand-binding site of RAGE was initially localised to the distal V1
domain [187]. However, recent studies have revealed that the C1 domain is an
additional ligand-binding domain; it binds to S100 proteins [188, 189]. Further,
antibodies against the C1 domain possess function-blocking properties both in vitro
and in vivo, suggesting a functional role for the C1 domain in ligand-receptor
interactions [II, 190]. In addition, the C2 domain of RAGE binds the soluble ligand
S100A12 [189]. RAGE itself can form dimeric and oligomeric complexes. This
suggests that RAGE may serve as a homophilic protein [191, 192, 193, 194, 195].
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In addition to HMGB1, RAGE binds to various other ligands and is called a
“pattern recognition” receptor that recognizes three-dimensional structures rather than
specific amino acid sequences in its ligands. This kind of ligand recognition is
common for receptors of the innate immune system [196]. Pattern recognition
receptors recognize pathogen-associated molecular patterns (PAMPs) that are
conserved microbial features not produced by the host itself [197].
Ligands in addition to HMGB1 and PAMPs include the amyloid-  peptide and
members of the S100 protein family [Figure 4, 198, 199]. Further, RAGE binds to
CD11b/CD18 integrin, and this mediates intercellular adhesion of leukocytes with
endothelial and epithelial cells [178, 200].
The closest homolog of RAGE in humans is ALCAM (CD166) (Figure 5).
ALCAM binds to S100b and its ligation activates NF- B [170]. Further, changes in
cytoplasmic localization of both ALCAM and RAGE have prognostic value in
cancers [201, 202]. These data suggest that ALCAM and RAGE share some common
functional characteristics.
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Figure 4. Schematic picture showing RAGE-interacting proteins and signaling
pathways. Modified from Rauvala and Rouhiainen [233].
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Figure 5. RAGE and ALCAM proteins show significant homology in
structures. Homology and domain searches of human RAGE and ALCAM were done
using tools in the website of National Center for Biotechnology Information
(Rockville Pike, Bethesda, MD, USA).
RAGE ligation by either HMGB1 or other ligands induces some common
pathways that result in cellular activation and cell motility [203]. Small GTPases
Cdc42, Rac, and Rap1 are involved in RAGE-mediated cell motility regulation [204].
Further, RAGE ligation induces transcription of RAGE gene itself by an SP1-
mediated mechanism [205]. RAGE ligands have both apoptotic and anti-apoptotic
roles [206]. Anti-apoptotic Bcl-2 expression is regulated by HMGB1-RAGE
interactions [207]. Thus far, the only signaling molecules known to bind directly to
the cytosolic tail of RAGE are ERK 1/2 and diaphanous-1 [203, 208].
Activation of the transcription factor NF- B is the most studied signaling
route  in  RAGE  biology.  NF- B  expression  is  required  for  RAGE  expression  [209].
NF- B activation by RAGE depends on the activation of the classical mitogen-
activated protein kinase (MAPK) pathway that involves also p38 MAP kinase and the
stress-activated protein kinase/c-Jun-NH2-terminal kinase (SAPK/JNK). In addition,
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HMGB1-RAGE ligation induces phosphorylation of the cyclic AMP response
element-binding protein (CREB), leading to its nuclear localization. Further, the
RAGE ligand S100b induces cytokine secretion from monocytes via a PKC-
pleckstrin-mediated pathway, suggesting their role in RAGE signaling [210]. In
endothelial cells, proinflammatory activity of S100 proteins seems to require
preactivation of endothelial cells and a dimeric form of S100 proteins [211].
A role for PKC proteins in RAGE signaling has been suggested in several
reports.  In  addition  to  monocytes,  RAGE  signaling  activates  PKC  in  muscle,
myocytes and endothelial cells [210, 212, 213].
The role of RAGE in neurobiology has been intensively investigated. The
original finding that RAGE is an HMGB1 receptor was made using brain neuron
culture as a model [76]. Later, amyloid-  peptide was shown to mediate RAGE-
dependent neuronal degeneration and to induce monocyte transendothelial migration
through the blood-brain barrier by activating endothelial cells by a RAGE-dependent
mechanism [198, 214]. The role of RAGE in diabetes-induced neuronal dysfunction
was studied recently. RAGE was shown to be a key mediator of diabetes-induced loss
of pain perception [215]. Further, RAGE ligation induces mitogenic signaling and cell
survival phenomena in neurons [216]. RAGE and HMGB1 have a significant role in
regeneration of peripheral nerves after nerve damage; blocking of either RAGE or
HMGB1 reduced nerve regeneration in a mouse model [217]. Recently, the role for
RAGE in endocytosis of S100b by Purkinje cells in spinocerebellar ataxia 1, a disease
leading to the loss of cerebellar Purkinje cells and brainstem neurons, was suggested
[218].
RAGE has several splicing isoforms that code for both transmembrane and
soluble proteins. Further, a soluble form of RAGE can be generated by proteolysis
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[219, 220]. The function of the soluble RAGE forms is poorly understood; a recent
study showed a correlation of plasma sRAGE levels to sepsis severity [221]. Further,
changes in plasma levels of sRAGE have been associated with many inflammatory
diseases [222]. Systemic administration of recombinant sRAGE inhibited leukocyte
adhesion to activated endothelium in a blood/retinal barrier model, and sRAGE has
protective effects in many diseases [223, 224]. However, sRAGE has similar effects
in RAGE-knockout mice, suggesting that it affects additional RAGE-independent
mechanisms [225]. This suggests that sRAGE is involved in inflammatory processes.
RAGE is posttranslationally modified: it contains disulfide bonds within its
Ig-domains, and its V1-domain is N-glycosylated. An amino terminal glycosylation is
suggested to have di-antennary complex glycosylation with core fucosylation,
whereas glycosylation in V1-Ig domain is more complex [226, 227]. Glycan moieties
mediate RAGE binding to HMGB1, regulate neurite outgrowth on HMGB1, and
mediate neutrophil migration through the endothelium [228, 229, 230]. In contrast,
RAGE glycosylation inhibits binding of other ligands. EN-RAGE and AGE-protein
binding to RAGE and signal transduction was enhanced by deglycosylation of RAGE
[231, 232]. These results suggest that both ligand affinity and specificity of RAGE are
regulated by glycosylation.
2.3.1.1 Gene expression induced by RAGE ligation
Ligation  of  RAGE  leads  to  changes  in  gene  expression.  Most  of  the  RAGE
ligands induce signaling pathways that lead to NF- B activation, which is the key
regulator of many genes involved in inflammatory mechanisms [233]. NF- B
activation is regulated by an evolutionary conserved signaling pathway where signals
derived from transmembrane receptors, like TLRs and IL-R1, activate NF- B in a
Myd88/IRAK and I B degradation-dependent manner [234].
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In addition to inflammatory response genes, some genes coding for
extracellular proteins and peptide precursors are upregulated by HMGB1-RAGE
interaction. These include members of the granin family and the immunoglubulin
superfamily [235, 236].
 The granin family consists of negatively charged proteins that are expressed
in the nervous, endocrine, and immune systems. Granins are involved in secretory
granule biogenesis [237, 238]. Chromogranin B is a member of the granin family
found in the nucleus in some cells, and it appears to affect transcriptional control of
several genes [239]. Further, granins are precursors of many biologically active
peptides. For example, an antibacterial peptide called secretolytin is derived from the
carboxy-terminal part of chromogranin B [240, 241].
In studies searching for HMGB1-inducible genes, Kuja-Panula et al. [235]
found a novel gene that was named AMIGO (amphoterin-induced gene and ORF). In
the same study, two other closely homologous genes were identified, AMIGO-2 and
AMIGO-3. All AMIGOs mediate homophilic binding. AMIGO was shown to be
involved in neurite faciculation. Later, Ono et al. [242] identified AMIGO-2 as an
Alivin 1 that is a neuronal survival promoting molecule. In addition, Rabenau et al.
[243] found that AMIGO-2 (called DEGA i.e. differentially expressed in human
gastric adenocarcinomas) mediates tumor cell migration and tumorigenicity. The role
of AMIGO-2 in cancer development was further supported by studies showing a
strong upregulation of AMIGO-2 in pancreatic cancer and in a lung cancer cell line
[244, 245]. The molecular mechanism of AMIGO-2 regulation in cancer was




The original work that demonstrated HMGB1 to be an extracellular molecule
utilized heparin-Sepharose chromatography to isolate neurite outgrowth-promoting
proteins. The strong heparin binding capacity of HMGB1 is suggestive of its ability to
bind cell surface proteoglycans. In fact, some proteoglycans, such as syndecan-1,
neurocan, and phosphacan, are known to serve as HMGB1 receptors [77, 81].
Syndecans are transmembrane cell surface protoglycans. There are four
members of syndecans in humans, syndecans 1-4, that are expressed widely in tissues.
Syndecan-1 is present in the endothelium, pre-B-cells, plasma cells, monocytes, and
macrophages [246, 247].  It inhibits leukocyte adhesion to the endothelium, and
migration through the endothelium and epithelium [248, 249, 250, 251]. Further, it
regulates angiogenesis in a glycosaminoglycan side-chain-dependent manner [252].
HMGB1 binds to syndecan-1 in a heparin and heparan sulphate-dependent
manner [81]. HMGB1 and syndecan-1 colocalize to the plasma membrane of mouse
epithelial cells. Binding of radiolabeled HMGB1 to epithelial cells is inhibited by
trypsin treatment of cells and by soluble heparin implying that cells may use
proteoglycan-type structures to bind HMGB1.
Neurocan is a matrix protein whereas phosphacan is a splicing variant of the
transmembrane protein receptor protein tyrosine phosphatase  (RPTP ) [77].
This suggests that the transmembrane form of RPTP  may mediate HMGB1-
induced signaling to the cytoplasm.
2.3.3 Lipids and carbohydrates
In  addition  to  protein-type  receptors,  HMGB1  binds  to  lipids  present  on  the
cell surface (I, IV). However, the roles of HMGB1-lipid interactions have not been
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extensively investigated. Further, binding of HMGB1 to different carbohydrates has
been described. These issues are discussed in the following sections.
An early report by Mohan et al. [79] described HMGB1 as a sulfoglucuronyl
glycolipid and sulfatide binding protein. Studies on HMGB1-platelet interactions
suggested a similar binding [I]. In the brain, both HMGB1 and sulfoglucuronyl
carbohydrates colocalize during development, but their possible cooperative function
in the developing brain is unknown [253]. In addition, HMGB1 binds to cholesterol-
3-sulfate, which modulates phosphorylation of HMGB1 [254].
The essential role of phosphatidylserine in phosphorylation of HMGB1 was
initially described by Ramachandran et al. [255] in a study demonstrating the role of
HMGB1 as a kinase substrate. Further, HMGB1 was shown to enhance transfection
efficiency of phosphatidylserine containing erythrocyte membranes in a DNA
transfection complex [256]. Later, HMGB1 was reported to bind directly to
phosphatidylserine and modulate its functions in an immune cell model [I, IV].
Extracellular HMGB1 was originally isolated as a binding component of
heparin, a carbohydrate [36]. HMGB1 was later found to bind carboxylated glycans
present in the proteins on the surface of different mammalian cell types [257]. These
glycans are recognized by monoclonal antibody GB3.1, which inhibits cell migration
[258]. One of the major core proteins recognized by mAb GB3.1 in tumor cells is
RAGE [257]. Glycosylation of RAGE enhances its binding to HMGB1 and modulates
HMGB1-dependent signal transduction [228].
2.3.4 Toll-like receptors
Lemaitre et al [259] were the first to describe the role of toll receptors in
immunity in 1996. This original finding was made using a fruit fly model. The role of
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toll-like receptors in immunity of other animals has been subsequently widely studied.
In mammals, 10 toll-like receptors are currently known [260].
HMGB1 has been described as a ligand of TLR2 and –4 and has been
suggested to activate inflammatory responses through the TLRs [78, 261, 262].
However, recent studies suggest that the genuine HMGB1 polypeptide alone does not
bind to the TLRs, and induction of an inflammatory response requires cofactors like
lipids or CpG-A [IV, 263].
2.3.5 Thrombomodulin
Thrombomodulin is a transmembrane protein that has an extracellular amino
terminal lectin-like domain, six epidermal growth factor domains, and an O-
glycosylation site-rich domain [264]. It regulates enzymatic activities of thrombin by
changing its function from a coagulation factor to an anticoagulant factor that
activates protein C. In addition to hemostatic functions, thrombomodulin has roles in
tumorgenesis, inflammation, and angiogenesis [265].
The amino terminal lectin-like domain binds to HMGB1 and inhibits its pro-
inflammatory activities [80]. Further, HMGB1 inhibits protein C activation by the
thrombin-thrombomodulin complex by a mechanism that does not involv the amino
terminal lectin-like domain, suggesting that HMGB1 may bind directly to protein C
and/or thrombin [266].
2.4. HMGB1 AND MECHANISMS OF INFLAMMATION
Inflammation is a host response to such harmful substances as pathogens,
injured cells, or irritants. Components of the vascular system mediate inflammatory
responses.
39
2.4.1 HMGB1 in cells of the vascular system
Blood cells circulate within vessels that are lined by endothelial cells. Vessels
can be categorized according into their function to three different classes, arteries,
veins, and capillaries. There are three major types of blood cells: red blood cells,
platelets, and leukocytes. The predominant circulating cell type is the red blood cell
(erythrocyte), numbering ~5 x 1012/l [267]. Platelets are the second most common
circulating cell type, at ~3 x 1011/l [268]. The third group of circulating cells is
leukocytes (or white blood cells), which consist of different sub-populations.
Neutrophils are most common leukocytes in blood, numbering 1.8-7.7 x 109/l [269].
Lymphocytes are the second most common leukocyte type in circulation, at 1-4 x
109/l. About two-thirds of these are T-cells and one-third B-cells. A small fraction of
lymphocytes belongs to the natural killer cell category. Monocytes comprise 3-8% of
leukocytes, numbering 0.3 x 109/l. Eosinophils, basophils, and mast cells are smaller
classes of leukocytes.
2.4.1.1 Platelets
Platelets are anucleated cells circulating in the vascular system. Their main
function is to prevent blood loss during endothelial and subendothelial damage.
Platelets are derived from megakaryocytes, myeloidic stem cells, in bone
marrow. Platelets are formed from filopodia extending through the endothelium
between the bone marrow and blood vessels directly to the circulation [270, 271]. In
circulation, when endothelial damage occurs or blood flow is perturbed, platelets start
to adhere to the subendothelial matrix or to each other [272].
Platelets contain only a small number of RNA and ribosomes that partly
originated from mitochondria [273]. However, platelets are capable of translation,
which can be induced by platelet activation [274, 275].
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Platelets  contain  four  types  of  secretory  granules  in  their  cytoplasm:  -
granules, dense bodies, lysozymes, and peroxisomes. The granule content can be
released to the extracellular space during platelet activation.
Platelets have adhesion receptors on their surface that can bind to the
subendothelial matrix at the site of endothelial damage. The two most important
receptors in primary adhesion are the collagen receptor glycoprotein IaIIa (GPIaIIa,
2 1, CD49b/CD29) and the von Willebrand –factor (vWF) receptor CD42. These
receptors are able to bind ligands even when the platelet is still at an unactivated state,
in contrast to CD41, which can bind fibrinogen and vWF ligands only after platelet
activation. Platelets can interact with the subendothelial matrix directly or via vWF,
fibronectin (Fn), laminin, or thrombospondin (TSP) [276]. Direct binding to collagen
usually occurs under low shear force and is mediated by GPIaIIa. Under high shear
stress, platelets bind to collagen via vWF and glycoprotein Ib-V-IX (GPIb/V/IX,
CD42) [277, 278, 279, 280].
Although primary adhesion to the subendothelial matrix does not require
platelet activation, adhesion induces signal transduction to the cytoplasm that may
result in cell activation. When the platelet is activated, it releases its contents of
secretory granules to the extracellular space, exposes phosphatidylserine to the outer
leaflet of the plasma membrane bilayer, and activates its adhesion receptors [281].
Platelets adhering to the endothelial damage site form a cell layer that can
bind more platelets to the same site via activated CD41 and fibrinogen [282]. This
forms a loose platelet plug. Activated platelets can induce aggregation of other
platelets by releasing activation factors such as ADP [283], gelatinase A [284], and
thromboxane A2 [276].  The phosphatidylserine surface, Ca
2+, Factor Va, and Factor
Xa form a reaction complex that catalyzes thrombin formation from prothrombin
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[285]. Thrombin is a major serine protease enzyme of the blood clotting cascade
[286]. It cleaves fibrinogen to fibrin, forming fibrin polymers which together with
platelets form a fibrin clot [285, 287, 288, 289]. Further, it is a potent platelet
activator. Fibrin formed due to proteolytic activity of thrombin are covalently linked
to each other by Factor XIIIa. Platelets in fibrin clots rearrange their cytoskeleton and
induce clot retraction, rendering the fibrin clot more resistant to shear stress [276].
Rapidly after its formation, the fibrin clot starts to be dissolved by plasmin.
Plasminogen (a plasmin zymogen) and t-PA released from the endothelium bind to
fibrin, forming a complex that catalyzes plasmin formation.
In addition to the role in thrombosis, platelets modulate immune responses
directly by expressing molecules involved in immunity, e.g. platelets can release
bactericidial peptides [268, 290, 291].
The HMGB1 mRNA and protein are expressed in platelets; however, the
function in platelets is not fully understood [I]. Of the suggested HMGB1
transmembrane receptors, platelets have been shown to express TLR-2, -4, -9 and
thrombomodulin [292, 293, 294]. The role of these receptors in platelet-HMGB1
interactions has not been elucitated.
Platelets have an important role in regulation of proteolytic cascades in the
circulation. Activated platelets express phosphatidyl serine on their surface, which
serves as a platform for coagulation factor activation complexes. Whether HMGB1
that binds to phosphatidylserine is able to affect coagulation factor activation on the
lipid surface is unknown.
Blood coagulation is regulated by both pro- and anticoagulant factors [295].
Abnormalities in the proteolytic cascades of the circulatory system are often
deleterious in sepsis and septic shock. For example, disseminated intravascular
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coagulation (DIC) causes ischemic necrosis in tissues. The role of HMGB1 in plasma
proteolytic systems has been examined and there are some hints suggesting that
HMGB1 is capable of enhancing proteolytic systems [266]. For instance, plasma
HMGB1 levels correlatinf with DIC [128]. Recently, HMGB1 was shown to bind
thrombomodulin and interfere with its functions [80, 266]. Thrombomodulin is a
protein that catalyzes thrombin-mediated protein C activation. Activated protein C is
an anti-inflammatory molecule that protects against septic shock. Its effect is
enhanced by heparin [296]. The in vivo effects of thrombin are potentiated by
HMGB1. These results suggest that HMGB1-mediated organ dysfunction may
involve increased thrombosis [266].
However,  in  another  proteolytic  system,  the  plasmin/plasminogen  system,  a
direct effect of HMGB1 has also been shown. HMGB1 enhances plasminogen
activation; however, HMGB1 itself is rapidly degraded by plasmin [39, 297].
Maruyama et al. [298] recently suggested a role for plasmin in the clearance of
systemic HMGB1 and Ali et al. [299] proposed that HMGB1 would inhibit
transendothelial transport of t-PA. Since HMGB1 may activate the
plasmin/plasminogen system, HMGB1 may also have anti-thrombotic functions.
Maruyama et al. [298], profiled a degradative activity on the endothelium,
protein “X”, which may mediate HMGB1 disappearance from the circulation. This
suggests that there may be other than proteolytic activities other than the plasminogen
system in the circulation that degrade HMGB1. Another study by Hagiwara et al.
[300] showed that the serine protease inhibitor nafamostat mesilate is able to decrease
plasma levels of HMGB1, probably via inhibition of I B, suggesting indirect effects
of serine proteases on HMGB1.
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Complement is another proteolytic cascade occurring in plasma, and it has a
role in both innate and adaptive immunity. The role of C5a receptor C5L2 in HMGB1
release during sepsis was recently shown [301].
2.4.1.2 Monocytes and macrophages
Monocytes and macrophages compose the monocytic cell lineage. Monocytes
are derived from bone marrow myeloid precursor cells and circulate in blood. They
are large cells that have a folded nucleus. When they emigrate to tissue, they start to
differentiate into macrophages. The main functions of monocytic cells are
phagocytosis, antigen presentation, and production of immune modulator molecules.
Phagocytosis involves removal of debris and foreign material. This leads to
localization of phagocytosed material inside the cells that may result in activation of
macrophages. Activation stimulates macrophage metabolism, motility, and
phagocytosis, and can lead to secretion of immune modulators like cytokines.
Cytokines are small ( 30 kDa) extracellular proteins that mediate signals to cells.
Cytokines bind to receptors on target cells and induce signal transduction to the
cytoplasm.
Monocytic cell surface receptors include scavenger receptors, adhesion
receptors, complement receptors, and recognition receptors. All of these receptors can
function individually or in concert to modulate monocytic cell responses to trauma,
cancer, or infection. Further, monocytic cells have a role in tissue modeling and
regeneration.
One of the current research interests is elucidating the role of HMGB1 in
regulation of dendritic cell maturation [181, 185, 302, 303]. Dendritic cells are
antigen-presenting cells. Monocytes are precursors of myeloid dendritic cells whereas
plasmacytoid dendritic cells, originate from cells of lymphoid lineage. Immature
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dendritic cells in tissue, when challenged by antigens, start to mature and move
towards lymph nodes where they can regulate adaptive immune responses [304].
HMGB1 has been shown to either enhance or suppress dendritic cell maturation; thus
its status in the dendritic cell maturation process remains poorly understood [54, 55,
359].
A very recent study indicated that HMGB1 mediates adaptive immune
responses against tumor cells. The response was TLR4-dependent and a naturally
occurring polymorphism in TLR4 was shown to affect HMGB1 interactions with
TLR4 [305].
2.4.1.3 Endothelial cells
The endothelium comprises the inner surface of blood vessels. It consists of 1-
6 x 1013 endothelial cells that are firmly associated together with tight junctions.
These tight junctions prevent accidental leakage of cells and macromolecules into
tissue. In normal conditions, the endothelium regulates transport of molecules and
cells to tissue in a highly sophisticated manner. When pathological events occur in
tissue, the endothelium can become activated and recruit inflammatory cells to the
damaged area. This usually occurs in the vessel walls of capillaries [306, 307].
2.4.2 Acute inflammation
In addition to sepsis and systemic inflammatory response, plasma HMGB1
levels are upregulated in other diseases. Suda et al. [308] reported that serum HMGB1
levels in surgery patients correlated with pre- and postoperative complications, and
Yasude et al. [309] detected high HMGB1 levels in serum, correlating with severity
of acute pancreatitis. Similarly, in cerebral malaria nonsurvivors had elevated levels
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of HMGB1 in plasma [310]. Further, elevated levels of HMGB1 in cerebrospinal fluid
were detected in bacterial meningitis [311].
The role of solid tissue HMGB1 in inflammatory diseases has been evaluated
in detail. In stroke, HMGB1 is upregulated and it has a significant role in mediating
inflammation and tissue injury [312, 313, 314]. A study by Liu et al. [315] revealed a
significant protective effect of intravenous anti-HMGB1 antibodies in rat ischemic
stoke. In ischemia-reperfusion of the liver, HMGB1 is upregulated and released, and
it mediates tissue injury that can be inhibited by anti-HMGB1 antibodies [316]. In a
kidney ischemia-reperfusion model, similar HMGB1 upregulation is seen [317, 318].
A recent study suggested a role for HMGB1 in skin “first-line defence”
rapidly after birth [319]. This suggests a role for HMGB1 in innate immunity in a
situation where adaptive immune system is still undeveloped. Similarly, involvement
in innate immune has been proposed for another secreted protein lacking signal
sequence, IL-1 . This implies common functions for nuclear cytokine-like molecules
IL-1  and HMGB1 [149].
2.4.3 Chronic inflammation
Another mechanism exploring the proinflammatory role of HMGB1 has been
tendered; an HMGB1-mediated inflammation induced by DNA. Extracellular DNA
has a potent role in the immune system. Eukaryotic methylated DNA activates
complement, induces macrophage activation in SLE, and forms antibacterial
neutrophil extracellular traps [55, 320, 321]. Unmethylated bacterial DNA is
recognized by TLRs and it is a highly proinflammatory material. HMGB1 binds to
both eukaryotic and prokaryotic DNA, and it can act as a carrier of DNA molecules to
immune cells to enhance proinflammatory responses [IV, 322]. Further, helper T-cell-
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mediated adaptive immune response in lupus is often directed against HMGB-
chromatin complexes [323, 324].
Plasma HMGB1 levels are upregulated in some chronic diseases studied.
Nowak et al. [325] described elevated plasma levels of HMGB1 in HIV patients with
clinical complications, and Yamada et al. [326] found elevated serum HMGB1 levels
in nonsurviving acute coronary syndrome patients. Further, in atherosclerosis;
HMGB1 expression in the plaque area is upregulated, and HMGB1 mediates cell
migration into lesions [327, 328, 329]. In arthritis, HMGB1 is upregulated and
HMGB1 blockade reduces disease severity [330].
RAGE has been linked to chronic inflammation in several diseases. Ligation
of RAGE activates NF- B and induces formation of oxygen radicals; both of which
are hallmarks of inflammation. Several inflammation-associated transcription factors,
i.e. NF- B and SP1, upregulate RAGE expression. These transcription factors are
further activated by RAGE ligation, leading to amplification of RAGE transcription
and resulting in a positive feedback loop that enhances inflammation. In addition,
accumulation of RAGE ligands in the matrix can cause chronic RAGE activation and
inflammation in diabetes and atherosclerosis [224, 331].
2.4.4 Sepsis and septic shock
Sepsis is one of most common causes of death. Sepsis may result from either
the immune response to severe infection or the response to endogenous factors [296].
The immunological response may in turn cause a systemic inflammatory response
and/or multiple organ dysfunction syndromes. The central role of TLR receptors and
their exo- or endogenous ligands in development of sepsis is currently accepted [296].
Blood plasma is a strongly anti-bacterial environment; it has several bacteria-
inhibiting mechanisms, including antibacterial peptides, phospholipases, and other
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microbicidal proteins, and lack of free iron [332, 333]. One indicator of sepsis is the
existence of living bacteria in circulation. Other indicators of sepsis comprice a
clinical assessment of infection together with systemic inflammatory reaction that can
include fever or hypothermia, increased heart or respiratory rate, and increased
leukocyte count [III]. In 1999 Wang et al. [64] showed that HMGB1 is upregulated in
plasma during sepsis and that HMGB1 can mediate lethality in sepsis. Later, up-
regulation of HMGB1 mRNA in blood cells was associated with poor outcome in
septic shock [334]. However, the relationship of HMGB1 protein levels in plasma to
sepsis severity, and especially to lethality, is currently controversial [IV, 335, 336,
337, 338, 339, 340]. Further, controversial results exist on about plasma HMGB1-
mediated lethality, questioning whether HMGB1 polypeptide alone would be lethal
[266, 341].
Some proteins, such as pancreatic elsatase, 1-antitrypsin, C-reactive protein,
and heat-shock proteins, express similar proinflammatory activities as HMGB1 when
bound to enhancing factors. Therefore, there are contradictory results in the literature
considering pro-inflammatory activity of these proteins [342, 343, 344, 345, 346, 347,
348]. Further, natural purified TLR ligands may be contaminated by other TLR
ligands, causing misleading experimental results [349]. Whether proinflammatory
activity of HMGB1 is mainly mediated by associated factors is currently under
investigation.
Although HMGB1 polypeptide itself may not mediate a strong pro-
inflammatory response, some studies clearly show protective effects of anti-HMGB1
antibodies in sepsis and systemic inflammatory response [64, 350, 351]. These studies
indicate that there is a mechanism that mediates deleterious effects mediated by
HMGB1. Disturbance of the epithelial cell layer by HMGB1 in a RAGE–dependent
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manner is one such mechanism [352, 353, 354]. In this model, exposure to HMGB1
leads to formation of nitric oxide and peroxynitrite within epithelial cells and results
in impaired epithelial function. A similar epithelial disturbance is seen in the lung,
where HMGB1 induces “an epithelial-mesenchymal transition” in a RAGE-dependent
manner that leads to pathological situations [355]. The role of RAGE in systemic
infection was further clarified in a study that, in addition to showing a protective
effect of RAGE blockade in severe sepsis, revealed RAGE independency in the
bacterial clearance within tissues [356].
Monocytes have a high concentration of HMGB1 and when monocytes are
activated they localize HMGB1 from the nucleus to the cytoplasm [II, 117]. This
cytoplasmic localization is suggested to be a prerequisite for secretion of monocyte
HMGB1. Recently, a role for intracellular HMGB1 in inflammation was suggested;
HMGB1  was  speculated  to  act  as  a  sensor  for  intracellular  LPS  or  cytosolic  DNA
[357, 358, 359].
Cytosolic  DNA  is  a  potent  immune  cell  activator.  This  activation  can  be
mediated by the DNA-dependent activator of IFN regulatory factors, the TANK-
binding kinase 1, or by components of inflammasome [360 ,361, 362]. Inflammatory
cytosolic DNA and its binding factors are considered to be exogenous, and
endogenous DNA is protected by the nuclear envelope. However, during cell division
the nuclear envelope becomes disrupted and nuclear DNA can be exposed to cytosolic
molecules. Therefore, nuclear DNA must be protected, possibly by the chromatin
structure [363].
2.4.5 Cholinergic anti-inflammatory pathway
The cholinergic anti-inflammatory pathway encompasses downregulation of
inflammation by a neural mechanism [364]. One major molecular mechanism that
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controls immune cells by neurons involves the 7 nicotinic acetylcholine receptor in
macrophages [365]. 7 nicotinic acetylcholine receptor-mediated effects lead to
decreased inflammation by reducing the levels of inflammatory mediators, including
HMGB1. Further, the control of associated atherothrombotic risk factors, increased
heart rate, and microinflammaton is suggested to be mediated by sympathetic or vagal
neural systems similarly as in the cholinergic anti-inflammatory pathway [366]. In
addition, nicotine, which acts via the 7 nicotinic acetylcholine receptors, has a
protective effect against immune system-mediated organ damage [317].
However, the cholinergic anti-inflammatory pathway is not the only neuronal
mechanism that interacts with the immune system. Infections in the periphery affect
neurotransmitter levels in the brain by a mechanism not mediated by the vagus nerve
[367]. Further, cytokines are known to alter emotional behavior [368]. For example,
HMGB1 has been suggested have a role in anorexia nervosa, and higher plasma
HMGB1 levels were detected during the refeeding resistance period [369, 370].
All of these data suggest that the nervous and immune systems cooperate in a highly
sophisticated manner, and they both have afferent and efferent effects on each other.
Stimulation of the vagus nerve using either chemical or electrical activation
inhibits HMGB1-mediated inflammation [371]. Activation of the vagus nerve leads to
release of acetylcholine, which binds to the 7 nicotinic receptors and can inhibit
tissue macrophages by downregulating the NF- B pathway [371]. Acetylcholine can
be mimicked by nicotine or other 7 acetylcholine receptor agonists, and these
molecules can decrease serum HMGB1 levels during inflammation [372, 373].
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Table 2. HMGB1 in human pathological states. Examples of changes in HMGB1
expression and correlations with clinical outcome.
Pathophysiological
state
HMGB1 expression Correlates with Reference
Anorexia upregulated daily energy intake and body
weight
72
Arthritis upregulated - 374
Atherosclerosis upregulated secretory phenotype of macro-
phages in fibrofatty lesions
327
Cancer upregulated tumor progression 68, 375, 376
Liver transplantation upregulated ALT 65
Myocardial ischemia,
stroke
upregulated more prolonged symptoms 377
HIV infection upregulated deteriorated immune status 378
Malaria upregulated lethality 310
Pancreatitis upregulated CRP, LDH, total bilirubin 309
Sepsis/septic shock upregulated DIC, SOFA, lethality 128
Sjögren’s syndrome  upregulated immunologic aberrations in
salivary gland biopsies
379
Surgery upregulated complications 308
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2.5. ANGIOGENESIS
Angiogenesis is a process leading to formation of new blood vessels during
development, growth, tissue repair, and tumor growth. For example, hypoxia induces
formation of new blood vessels [reviewed in 380]. The endothelial cell layer of a new
vessel is formed by either dividing existing endothelial cells or through recruited
endothelial precursor stem cells called angioblasts.
Expression of HMGB1 is upregulated in hypoxic tissues, and HMGB1 was
found to be an angiogenetic switch molecule that promotes vessel formation [381,
382, 383, 384]. In addition, RAGE is upregulated in hypoxia and is involved in
angiogenesis, especially in formation of microvessels within tumors [206, 385].
HMGB1  and  other  sRAGE  ligands  upregulate  vascular  endothelial  growth  factor
(VEGF) and regulate angiogenesis [232, 386, 387, 388]. Although VEGF is
upregulated by HMGB1 in tumors, it does not appear to have a role in HMGB1-
dependent vessel formation in developing bone [21, 386].
In  addition  to  RAGE,  other  HMGB1  receptors,  syndecan-1,  and
thrombomodulin, are involved in angiogenesis [252, 389]. Further, the angiogenic
mechanism involves HMGB1-mediated homing of endothelial precursor cells [390].
Results of these studies indicate that HMGB1 and its receptors have a crucial
role in controlling new vessel formation.
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3. AIMS OF THE STUDY
The aim of this study was to investigate the functions of HMGB1 in cells and
plasma of the circulatory system under physiological and pathophysiological
conditions.
Specific aims were as follows:
1) To investigate the expression and functions of HMGB1 in anucleated cells
to reveal other functions besides those associated with nuclear DNA
binding. The study was done using platelets as model cells.
2) To evaluate the role of extracellular HMGB1 in mononuclear cells.
Specifically, the role of HMGB1 in monocyte adhesion and migration and
in macrophage activation was investigated. Further, the specific HMGB1
secretion mechanism was examined in detail.
3) To elucidate the mechanism of HMGB1-mediated inflammation using
both in vitro and in vivo models. Both primary and transformed
mononuclear cells were used in in vitro cell culture studies. In vivo studies
were carried out using arterial thrombi samples and serum samples derived








Immunofluorescence microscopy I II
Cell adhesion assay I II
Enzyme activity measurement I II
Western blotting I II III
Enzyme-linked immunoabsorption assay I II III IV
Affinity and ion exchange chromatographies I II IV
DNA quantification I II IV
Reverse transcriptase PCR I II IV
Antibody production  II
Endotoxin analysis  II
Immunohistochemistry  II
Cell migration assay  II
Statistical analysis  II III IV
Recombinant protein production  II IV
Cell culture  II IV
Mass analysis IV
Database searches IV
Solid-phase binding assay IV
Phospholipid vesicle production IV
Nitric oxide assay IV
Table 3. Experimental procedures used in studies I-IV. Detailed descriptions
of materials and methods can be found in the original publications at the end of this
thesis. The original publications are referred to by their Roman numerals.
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4.1 Additional exprimental procedures
4.1.1 Northern blot of platelet RNA
Platelet RNA was isolated from two units (120 ml) of one-day-old leukocyte-
free platelet concentrates (Finnish Red Cross Blood Transfusion Service, Helsinki,
Finland). RNA was electrophoresed in 1.2% agarose gel and blotted to nylon
membrane. HMGB1 mRNA was detected with dioxigenin-labeled rat HMGB1 anti-
sense RNA-probe (a kind gift from Dr. R. Nolo) and anti-dioxigenin alkaline
phosphatase conjugated Fab´ antibody (Boehringer-Mannheim, Mannheim,
Germany). Color was developed with 5-bromo, 4-chloro, 3-indolylphosphate/nitro-
bluetetrazolium staining [28].
5. RESULTS
5.1 Expression of HMGB1 (I, II, IV)
 Western blotting of platelet and mononuclear cell lysates with affinity-
purified anti-HMGB1 antibodies revealed a 30-kD band that migrated with
recombinant HMGB1. Further, anti-HMGB1 detected a 30-kDa band from microglial
and endothelial cell lysates in Western blotting analysis. Biochemical characterization
revealed that a similar 30-kDa protein from platelet or monocyte lysates bound to
heparin-Sepharose and was eluted with 0.6-0.75 M NaCl, in a similar manner to rat
brain HMGB1, and it was recognized by anti-HMGB1 antibodies.
The levels of HMGB1 in platelets and monocytes were assessed by measuring
the intensity of the immunoreactive 30-kDa band in Western blotting. The amount of
HMGB1 was estimated to be 0.01o/o of  total  platelet  protein,  and  0.5%  of  total
monocyte protein. Thus, in monocytes, the HMGB1 concentration was approximately
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50 times higher that in platelets. Quantitative estimation of HMGB1 polypeptide in
platelets revealed that 0.01% of total protein corresponds to about 85 ng protein/109
platelets. This corresponds to approximately 2x103 HMGB1 polypeptides/single
platelet.
5.2 Structural analysis of HMGB1 (IV)
Structures of both recombinant and tissue-derived HMGB1 were studied.
Recombinant proteins were produced in S9 baculovirus and purified with heparin-
Sepharose and ion exchange chromatography. Tissue HMGB1 was isolated from
young rat brain with a two-step chromatography method utilizing heparin-Sepharose
and Affi Gel Blue chromatography. SDS-PAGE and mass spectrometric analyses
showed that the recombinant HMGB1 has one intrachain disulfide bond in it’s a box.
Mass spectrometric analyses of tissue HMGB1 indicated that its major form lacks the
carboxyl terminal glutamic acid residue, and the minor form is the full-length protein.
Further, SDS-PAGE analysis revealed a similar oxidation stage in both recombinant
and tissue-derived HMGB1 (IV). In silico analyses suggested that the lack of the
glutamic acid residue is not due to changes in the HMGB1 transcript.
 5.3 Identification of HMGB1 mRNA in platelets and monocytes (I)
Analysis of HMGB1 mRNA in platelets using RT-PCR resulted in a strong
amplification of a band of expected size. Amplification of monocyte mRNA under
identical conditions resulted in an intensive band of the same size. To exclude
leukocyte contamination in the platelet preparation, amplification of the cDNA
encoding CD18 was assayed. No amplification was observed in the platelet cDNA
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preparation by using primers specific for the CD18, whereas amplification of
monocyte cDNA under the identical conditions resulted in a strong 350-bp band.
Northern  blotting  revealed  the  existence  of  three  major  forms  of  HMGB1
mRNA in platelets (Figure 6).
Figure 6. Northern blot of platelet HMGB1 mRNA. A) Ethidium bromide
staining of ribosomal RNA. B) HMGB1 antisense staining. kb=kilobase.
5.4 Subcellular localization of HMGB1 in platelets and monocytes (I, II)
Immunostaining and biochemical methods were used for in vitro studies of
resting and activated platelets and mononuclear cells. In immunofluorescence
microscopy studies, staining of nonpermeabilized thrombin-activated platelets or
resting permeabilized platelets with anti-HMGB1 antibodies revealed staining within
platelets and at the surface of activated platelets. No staining was observed in resting
nonpermeabilized platelets. In monocytes, immunofluorescence microscopy studies
revealed adhesion-dependent surface expression of HMGB1. Characteristic for the
staining was the occurrence of HMGB1 as intense patches at the cell surface.
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Immunoreactivity of HMGB1 in pre-embedding electron microscopy studies
was observed at the cell surface of the collagen-activated platelets, whereas there was
no immunoreactivity on the resting platelets. Post-embedding cryosection electron
microscopy in turn indicated intracellular localization of HMGB1 in platelets. In both
collagen-activated and resting platelets, numerous gold particles immunoreactive to
HMGB1  were  localized  in  the  cytoplasm.  The  activated  platelets  displayed  a
significant number of gold particles at the cell surface, in contrast to the resting
platelets.
Most of the HMGB1 was found in the cytoplasmic fraction of resting platelets
after subcellular fractionation. Some of HMGB1 was also present in the membrane
fraction, whereas a negligible amount was detected in the granular fraction.
Partitioning of HMGB1 to the 100 000 g soluble fraction of resting platelets indicates
its localization to nonvesicular structures in the platelet cytoplasm. Further, HMGB1
was not associated with the platelet cytoskeleton.
Expression of HMGB1 was studied in vivo using frozen sections of arterial
thrombi containing adherent monocytes and platelets. Strong HMGB1
immunoreactivity was seen within mononuclear cells, and a fainter extracellular
reactivity was present in regions populated by mononuclear cells.
5.5 Secretion of HMGB1 (I-III)
Immunostainings of activated platelets and monocytes revealed that they
secrete HMGB1. Since mononuclear cells had a much higher expression level of
HMGB1, we further studied the secretion using the transformed murine macrophage
cell line RAW 264.7 as a model.
RAW 264.7 cells secreted HMGB1 after treatment with 20 ng/ml IFN-  or 10
nM PMA. The kinetics of secretion was slow, taking several hours. Secretion did not
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correlate with LDH-leakage, suggesting an active secretion process. Secretion of
HMGB1 was dose-dependently inhibited by the ABC1 inhibitor DIDS, and 100 M
DIDS completely inhibited amphoterin secretion. IL-1  secretion  was,  as  reported
earlier, also inhibited by DIDS. An ABC1 inhibitor, glyburide, inhibited both
HMGB1 and IL-1  release.  However,  even  at  high  concentrations  of  glyburide,  the
inhibition was only partial. Another ABC-1 inhibitor, BSP, inhibited IL-1  secretion,
but not HMGB1 secretion.
In  vivo  release  of  HMGB1  from  mononuclear  cells  was  observed  within
thrombi in immunofluorescence studies. Further, in vivo release of HMGB1 under
different clinical circumstances, namely in sepsis and septic shock, also occurred.
5.6 HMGB1 as an adhesive and migration-promoting molecule (I, II, IV)
Both resting and activated platelets bound to the HMGB1-coated surface, and
platelet activation increased the binding approximately threefold. The binding of
resting platelets to fibrinogen was about three times higher than to HMGB1, whereas
activation reduced the difference. Platelet binding to HMGB1 was divalent cation-
independent. A difference in adhesion mechanism was found between resting and
activated platelets using heparin in the culture medium. Soluble heparin inhibited
binding of resting platelets to HMGB1, while it had no effect on activated platelet
binding. Further, other glycosaminoglycans inhibited resting platelet binding to
HMGB1, but less efficiently than heparin.
Most of the platelets bound to HMGB1 in the presence of activation inhibitors
exhibited the spiculated morphology, with a round cell body and long thin filopodia.
Lamellipodia were absent in most of the cells. Only about 30% of the platelets bound
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to HMGB1 were spread and flattened. Most of the platelets bound to fibrinogen in the
presence of activation inhibitors had lamellipodia and numerous filopodia.
When peripheral blood leukocytes were allowed to adhere to immobilized
HMGB1,  fibronectin,  or  albumin,  CD14–positive  cells  bound  to  a  similar  extent  to
microwells coated with HMGB1 or fibronectin, whereas only low binding was
observed on wells coated with albumin. The total number of adhered leukocytes was
two- to threefold higher on fibronectin than on HMGB1. Interestingly, almost all cells
adhering to HMGB1 were CD14-positive, whereas half of the cells adhering to
fibronectin were CD14-negative.
Morphology of the CD14-positive cells adhering to the HMGB1 surface was
strikingly different then that of the cells adhering to the fibronectin or vitronectin
surface. Cells adhering to HMGB1 demonstrated remarkably flattened morphology
and large lamellipodia compared with fibronectin or vitronectin-adherent cells.   The
surface area of HMGB1-adherent cells was clearly larger than that of fibronectin-
adherent cells. In contrast, rat brain migroglial cells did not display differential
spreading on HMGB1 and fibronectin.
Since HMGB1 was strongly adhesive for monocytes and adhesion induced
drastic morphological changes in monocytes, we tested whether HMGB1 has any role
in monocyte migration. Migration of monocytes across porous filters was studied
under two different conditions, either porous membrane was used alone as a barrier or
it was layered with endothelial cells. HMGB1 was not chemotactic in migration
assays across uncoated or endothelium-coated polycarbonate filters. In
transendothelial migration assay, TNF -activated endothelial cells were used.
Migration was significantly and dose-dependently inhibited by anti-HMGB1
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antibodies. Further, the role of RAGE in transendothelial migration was suggested in
studies utilizing anti-RAGE or soluble RAGE fragments.
5.7 Role of RAGE as an HMGB1 receptor (II)
RAGE  was  detected  in  human  and  rat  monocytes  by  Western  blotting  of
HMGB1-adherent  cells,  and  the  role  of  RAGE  as  an  HMGB1  receptor  in
mononuclear cells was studied. RAGE-mediated gene expression and cell adhesion
and migration were assayed. Upregulation of chromogranins has been identified as a
hallmark of HMGB1-RAGE interactions. We investigated whether mononuclear cells
express, in addition to chromogranin B, chromogranin C and whether the expression
of chromogranins is upregulated by HMGB1. RT-PCR revealed a band of expected
size for chromogranins B and C in both monocytes and microglial cells.
Chromogranin B and C expression in HMGB1-adherent monocytes was not altered
after culture for one hour when compared to fibronectin adherent cells. However,
chromogranin B was strongly upregulated after adhesion to HMGB1 for 20 hours in
both monocytes and microglia compared with fibronectin-adherent cells.
Chromogranin C mRNA was not upregulated in monocytes or microglia during
adhesion.
The role of RAGE in adhesion and spreading of monocytes to immobilized
HMGB1 was evaluated using sRAGE as a spreading inhibitory agent. sRAGE
inhibited spreading on HMGB1, whereas the control immunoglobulin superfamily
protein, sAMIGO, had no effect.
5.8 Lipids as HMGB1-binding components (I, IV)
HMGB1 binds to sulfatide and to other glycolipids. Thus, the binding of
HMGB1 to other lipids was also assayed. In a 2D-TLC overlay assay, iodinated
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amphoterin bound to two spots of platelet lipid extract. The spots were identified as
phosphatidylserine and phosphatidylethanolamine due to their RF values and
ninhydrin staining. In ELISA assay, HMGB1 bound strongly to phosphatidic acid and
phosphatidylserine. Binding of HMGB1 to lipids was divalent cation-independent.
Further, recombinant HMGB1 produced in E. Coli carried lipids that were
partly identified as phospholipids. In addition, organic solvent-soluble
proinflammatory substances could be extracted from bacterially produced HMGB1.
Whether these active organic solvent substances were lipids was not further analyzed.
5.9 HMGB1 in diseases and in inflammation (II-IV)
Serum samples of patients with severe sepsis and septic shock were analysed
for concentration of HMGB1. HMGB1 was upregulated in serum during sepsis and
septic shock, as were other proinflammatory cytokines, including IL-6, IL-8, IL-10,
and TNF- .
Both tissue-derived and recombinant eukaryotic HMGB1 exhibited only a
relatively low proinflammatory activity compared with bacterially produced HMGB1.
Bacterially produced recombinant HMGB1 was found to contain organic solvent
soluble material that possessed proinflammatory activity. In addition, HMGB1 bound
to bacterial DNA in an affinity chromatography assay.
Two different in vivo models were used to explore expression of HMGB1
during inflammatory conditions in humans. First, expression of HMGB1 was detected
in arterial thrombi, which contained adherent monocytes, platelets, and fibrin. The
presence of HMGB1 in mononuclear cells in vivo was detected. Second, the
expression of HMGB1 was studied in serum samples of patients with severe sepsis
and septic shock, and high levels of HMGB1 expression were measured compared
with healthy controls.
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The serum levels of HMGB1 did not correlate with disease severity, nor did
they correlate with the other cytokines tested. Serum HMGB1 concentration remained
high during the test period (0-144 hours), in contrast to other cytokines, in which
serum concentration decreased.
6. DISCUSSION AND CONCLUSIONS
We investigated the role of HMGB1 in cells of circulation and in
inflammatory cells. HMGB1 is expressed in platelets, mononuclear, and endothelial
cells, and it acts as a mediator of immune cell adhesion and migration. The genuine
HMGB1 polypeptide is only a weak proinflammatory cytokine, and it appears to act
as an activator when complexed to DNA and lipids.
6.1 HMGB1 in platelets
Since platelets are anucleated cells we investigated whether they express
HMGB1, which would have then some other function than nuclear DNA binding.
Platelets were found to contain both HMGB1 mRNA and protein [I]. Others have
later confirmed the expression of HMGB1 mRNA in platelets using microarray
analysis [391].
The amount of HMGB1 in platelets was low when compared with the amount
found in leukocytes. However, studies with IL-1  RNA have shown that platelets
have the capacity for RNA splicing and translation, phenomena occurring after
platelet activation [392]. A similar splicing phenomenon was suggested to play a role
in platelet HMGB1 RNA processing, suggesting that platelets may synthesize
HMGB1, yielding more significant HMGB1 concentrations within platelets [392].
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Activated platelets expressed HMGB1 on their surface. Surface HMGB1 most
probably originated from the platelet cytoplasm since in both electron microscopy and
subcellular fractionation analyses of resting platelets intracellular HMGB1 was
diffusively associated with the cytoplasm, and not with secretory vesicles.  Thus,  the
secretion mechanism seems to differ from the mechanism suggested for monocyte
HMGB1 secretion, which involves a vesicular mechanism [126]. Further, the
HMGB1 secretion route in platelets differs from the nucleated cell secretion route
since it bypasses the nucleus to cytoplasm transport, which is suggested to have a role
in active HMGB1 secretion in some cells [126].
Surfaces coated with exogenous HMGB1 induced platelet adhesion and shape
change to a spiculated form. Shape change is a one marker of platelet activation,
suggesting that HMGB1 is a platelet-activating agent. The platelet cell surface
binding receptor for HMGB1 is currently unclear, and it is unknown how HMGB1
signals in platelets. Platelet lipids, phosphatidyl serine and phosphatidyl
ethanolamine, can bind to HMGB1 but protein-like platelet receptors remain to be
clarified [I]. Platelets do not possess RAGE, but they express TLR2/4, suggesting a
possible role of TLRs in platelet-HMGB1 interactions [292, 293, 393].
Spiculation of HMGB1-bound platelets resembles the migratory phenotype of
cells.  Induction  of  migration  is  one  of  the  well-known  functions  of  extracellular
HMGB1. This suggests that HMGB1 may mediate platelet migration. Migration of
platelets has been studied little, but chemotaxis and transendothelial migration of
platelets have been described [394, 395]. Whether exogenous HMGB1 would be
chemotactic for platelets is unknown. HMGB1 is not chemotactic for monocytes,
probably due to their high endogenous HMGB1 content [II, 396]. HMGB1 might
mediate chemotaxis of platelets that have only low levels of the endogenous protein.
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HMGB1-induced platelet activation may have a role in sepsis and septic
shock, where DIC, which involves platelet activation and coagulation, often occurs.
Indeed, HMGB1 levels in plasma correlate with DIC, and systemic HMGB1 has been
shown to promote coagulation [128, 266]. Again, further studies are required to
clarify the role of HMGB1 in platelet biology in vivo.
6.2 HMGB1 in monocytes
In addition to platelets, leukocytes and endothelial cells were found to express
HMGB1. Especially monocytes express high levels of HMGB1 and secrete it after
activation. Extracellular HMGB1 mediates monocyte migration and promotes
inflammatory responses of mononuclear cells.
The role of HMGB1 in transendothelial migration of cancer cells has been
previously demonstrated [397]. In our study, the essential role of HMGB1 in
transendothelial migration of the monocytes was revealed for the first time [II]. The
results show that blocking either HMGB1 or RAGE inhibits transendothelial
migration. This indicates that these proteins play a critical role in monocyte
diapedesis.
HMGB1-mediated cell migration most likely occurs with an autocrine
mechanism or with a mechanism involving matrix-bound HMGB1 since soluble
exogenous HMGB1 is not chemotactic for monocytes [II, 396]. High endogenous
monocyte  HMGB1  concentration  may  cause  inability  of  monocytes  to  respond  in  a
chemotactic manner to exogenous soluble HMGB1. However, substrate-bound
HMGB1 induces rapid and extensive monocyte spreading, suggesting a role for
exogenous HMGB1 in monocyte motility. In contrast to monocytes, tissue
macrophages do not spread on the HMGB1 surface, suggesting that peripheral blood
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monocytes  respond  to  HMGB1  using  a  mechanism  that  differs  from  tissue
macrophage response.
Chromogranins B and C are neuroendocrine secretory granule proteins that are
members of the granin family. In this study, chromogranin C expression was
described for the first time in monocytes. Chromogranins B and C are precursors of
various biologically active peptides, some affecting the immune system [398]. For
example, the concentration of secretolytin, a chromogranin B-derived antibacterial
peptide, is increased during surgery, suggesting secretolytin´s role as an innate
immunity molecule [399]. Secretoneurin is a peptide derived from chromogranin C
that induces leukocyte migration [398]. Both chromogranin B and C and the peptides
derived from them are detected in human plasma [398]. However, the roles of
chromogranin B and C in mononuclear cells and in circulation remain poorly
understood.
RAGE is the major HMGB1 receptor in macrophages, and it mediates
inflammatory and migratory responses of HMGB1 [III, 400]. In the literature, the
majority of studies considering HMGB1 and its receptors focus on HMGB1/RAGE
interactions. This should not diminish the importance of other cell surface molecules
as HMGB1 receptors functioning in vivo. In fact, the clear differences in phenotypes
of HMGB1 and RAGE knockouts  HMGB1 knockouts are lethal- whereas RAGE
knockouts are alive and fertile  suggest that cells utilize RAGE-independent
mechanisms to interact with HMGB1. Further, the RAGE binding site in HMGB1 is
localized to the carboxyl terminal part of B box [397]. However, the recombinant A
box of HMGB1 is able to antagonize the effects of full-length HMGB1 in cells of the
circulatory  system,  suggesting  that  cells  have  receptors  other  than  RAGE to  bind  to
the HMGB1 A box [129].
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Mononuclear cells express other HMGB1 receptors, e.g. TLR2/4, syndecan-1,
and CD14 may interact with HMGB1 [II, 247, 260]. The role of TLR2 in cell
migration has recently been studied. TLR2 can induce cell migration via both inside-
out and outside-in signaling [401, 402]. Whether HMGB1 can affect cell motility via
TLR2 is unknown.
TLR4 does not bind to genuine HMGB1, but is precipitated with HMGB1
from cell lysates, suggesting that HMGB1 containing TLR4 binding complexes exist
[78, 262]. Currently, it is well accepted that many TLRs recognize their ligands
presented in complexes with endogenous proteins. These include CD14, LBP, MD-2,
glycosphingolipids, and dectin-1 [403, 404]. In this study, we found that all peripheral
blood leukocytes that adhere to HMGB1 were CD14-positive. Very recently, HMGB1
was reported to bind to both CD14 and MD2, and HMGB1 signaling is dependent on
CD14 expression. This suggests that CD14 serves as a monocyte HMGB1 receptor
[82, 405, 406]. Another report showed that HMGB1 binds to LPS and mediates its
binding to CD14 [357].
6.3 Nonclassical secretion
Activated mononuclear cells secrete HMGB1, and the secretion is not due to
cell necrosis [II]. Our results suggested a role for PKC activation in macrophage
HMGB1 secretion since cell activation with PMA induced HMGB1 secretion. Later
Oh  et  al.  [407]  have  subsequently  confirmed  the  role  of  activated  PKC  in  HMGB1
secretion from macrophages. Similar activated PCK-mediated HMGB1 secretion
occurs in erythroleukemia cells [408].
Secretion in monocytes utilizes a mechanism that is inhibited by DIDS [III].
This strongly suggests that secretion is an active process and that secretion involves
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either DIDS-inhibitable ABC transporters or HCO3
-/Cl- channels. Indeed, mouse cells
lacking ABCC1 have a decreased capacity to secrete HMGB1 [27, 162].
Some mechanisms involved in nonclassical secretion have been further
clarified. Recent studies have indicated that when the secreted protein in the
cytoplasm is localized to the cytoplasmic side of the plasma membrane it may be
passively translocated (diffused) to the extracellular space [409]. Close localization to
the membrane may involve membrane lipid binding and membrane perturbation.
Since passive diffusion is bidirectional, the protein secreted to the extracellular space
should be trapped on the extracellular side to prevent diffusion back into the cell. This
is in fact the case in the secretion of FGF-2. The secretion of FGF-2 occurs in an
energy-independent manner and does not require protein unfolding, but is dependent
on extracellular trapping of FGF-2 by cell surface heparan sulfate proteoglycans. A
similar secretion mechanism has been suggested for the lectin CGL-2, which binds to
both glycolipids and glycoproteins. HMGB1 binds to membrane lipids and HSPGs,
and its secretion most probably does not require protein unfolding [I, II, IV, 81, 120].
Whether it is secreted similarly to FGF-2 remains to be clarified.
6.4 Inflammation
It  is  now  clear  that  HMGB1  is  released  from  the  cells  in  various  types  of
inflammatory diseases and that extracellular levels of soluble HMGB1 often correlate
with  disease  severity.  In  addition,  the  ability  of  anti-HMGB1  antibodies  to  protect
against tissue injury and death in various animal models is unambiguous. However,
there are contradictory results, for how plasma/serum HMGB1 levels correlate with
lethality in inflammatory diseases. This suggests that the protective mechanism of
anti-HMGB1 antibodies may involve blocking of HMGB1 in solid tissues or at the
cell surface rather than blocking of the circulating plasma HMGB1.
68
Results in this study clarified for the first time that genuine HMGB1 has only
a weak proinflammatory activity and that HMGB1 levels in serum do not correlate
with lethality in sepsis and septic shock [III, IV]. Our results further demonstrate that
HMGB1 can mediate proinflammatory reactions by binding adjuvant molecules,
lipids,  and  DNA.  Others  have  later  shown  that  HMGB1  complexed  with  DNA
mediates proinflammatory reactions via TLR9, and HMGB1 complexed with IL-1
induces proinflammatory reactions in an IL-1 receptor-dependent manner [55, 410].
6.4.1 Brain ischemia/reperfusion
Within the past three years, several studies on the role of HMGB1 in brain
inflammation have been published. Brain ischemia induces massive injury that is
associated with inflammation. The inflammatory response may have both harmful and
protective roles. The effects of the inflammatory response are different at the different
time-points after the insult. The role of HMGB1 has been studied using animal
models, and its serum levels have been measured in human diseases.
Soon (within the first hours) after experimental ischemia-reperfusion, HMGB1
is translocated from the nucleus of neurons to the cytoplasm. Translocation occurs to
a lesser degree in astrocytes and oligodendrocytes [314, 315, 411]. The overall
expression level of HMGB1 protein is unchanged [411]. At the same time, HMGB1 is
found in cerebrospinal fluid [411]. Elevated levels of HMGB1 in serum are seen in
both experimental ischemia-reperfusion models and in human patients with cerebral
ischemia [313, 377, 411]. After one day, HMGB1 disappears from the nuclei of
neurons, but can be seen in degenerating neurons in ischemic areas [314].
Blocking of HMGB1 using antibodies or RNA inhibition protects against
brain injury in a rat experimental ischemia-reperfusion model. RNA inhibition studies
have indicated that blocking of just brain-derived HMGB1 is sufficient to explain the
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protective effects seen in HMGB1-antagonized animals [313]. One proposed
mechanism is blockade of the microglia-mediated inflammatory response that occurs
several hours or days after the insult [313, 315].
The molecular mechanism that can connect neuronal HMGB1 release during
early events of ischemia and late microglial infiltration and activation has been
clarified by recent studies. Exogenous HMGB1 upregulates gene expression in target
cells, leukocytes, and astrocytes, and especially the expression of chemokines seems
to be strongly enhanced by HMGB1 [63, 396]. Chemokines are molecules that attract
leukocytes to the injured tissue. Thus, ischemia-induced neuronal HMGB1 release
may activate astrocytes to release chemokines, then astrocytes in turn attract activated
macrophages to the area. These activated immune cells may then worsen tissue
damage.
6.4.2 Liver ischemia/reperfusion
In liver ischemia-reperfusion, the role of HMGB1 has been studied in detail.
In a mouse model, hepatic HMGB1 levels increase after insult during the first 12-24
hours, then decreasing [316, 412]. Similarly, plasma levels of HMGB1 are
upregulated [412]. As in the brain ischemia-reperfusion model, anti-HMGB1
antibodies protect against tissue injury [316, 412].
The behavior of HMGB1 in human liver transplantation resembles that
behavior of HMGB1 in the mouse ischemia-reperfusion model [65]. HMGB1 is
massively released after reperfusion of transplanted liver, but the release rapidly
declines, probably due to milder ischemia-reperfusion injury in human liver than in
the experimental mouse model. Further, plasma HMGB1 levels correlate with alanine
aminotransferase, suggesting that HMGB1 is released because of the liver injury [65].
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6.5 Conclusions
In this work, the role of HMGB1 in circulatory cells has been investigated.
Results obtained from in vitro studies were utilized to extend this work to in vivo.
HMGB1 is expressed in platelets that are anucleated cells, indicating that
HMGB1 has functions other than nuclear chromatin binding. Platelet adhesive
function is suggested for HMGB1. Further, adhesion to HMGB1 activates platelets,
indicating that HMGB1 may be called a platelet activating factor. These results show
for the first time that HMGB1 is expressed and has some functions in anucleated
cells.
In addition to platelet adhesion and activation, HMGB1 mediates monocyte
adhesion, migration, and activation. The results showing adhesive functions for
monocytes are in parallel with findings of previous studies where HMGB1 has
mediated adhesion and motility of various cell types.
Elevated HMGB1 levels in circulation during sepsis and septic shock are in
parallel  with  previous  reports.  However,  the  correlation  of  HMGB1  levels  with
lethality in an earlier report could not be confirmed here. Currently, it is unclear how
HMGB1 levels correlate with lethality in sepsis and septic shock.
Finally, our results are the first to show that the genuine HMGB1 polypeptide
only displays a weak proinflammatory activity, but it may mediate proinflammatory
reactions in complex with other molecules such as lipids and DNA. Others recently
have reported similar results.
In conclusion, HMGB1 is released from immune cells both in vivo and in vitro, and it
mediates cell migration and activation. The in vitro immune cell activation is
enhanced with HMGB1-bound adjuvant molecules. HMGB1 may act in vivo as an
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immune activator that mediates cell motility and recognizes infectious or damage-
associated molecular patterns.
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Figure 7. HMGB1 signaling to the cytoplasm is mediated by transmembrane
receptors. Direct HMGB1 signaling from the cell surface to the cytoplasm is mediated
by  RAGE  (A).  HMGB1  in  complex  with  DNA  signals  via  RAGE  and  TLR9  in
lysosomal vesicles (B). A lipid-bound HMGB1 may bind to CD14 and/or MD2 on the
cell surface and induce signaling via TLR4 (C).
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Figure 8. Proposed functions of HMGB1 and its cell surface receptors in a vessel of
inflamed or necrotic tissue. The endothelium is activated in inflamed tissue, and it
starts to express adhesion molecules to leukocytes, which then migrate through the
endothelium to the inflamed area. Migrated monocytes mature to tissue macrophages.
HMGB1 induces chemokine release from macrophages and other tissue cells, e.g.
astrocytes. Chemokines attract more immune cells to the inflamed area. In trauma, the
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endothelial cell layer is damaged and platelets adhere to the subendothelial matrix.
Adhesion activates platelets, which then release HMGB1, further activating the
platelets. In addition, platelet-derived HMGB1 can mediate platelet/monocyte
interactions. MC = monocyte, Mp = macrophage, As. = astrocyte or other tissue cell.
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